Compare SEB & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEB | XENE |
|---|---|---|
| Founded | 1918 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.2B |
| IPO Year | 1994 | 2014 |
| Metric | SEB | XENE |
|---|---|---|
| Price | $5,197.88 | $52.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $68.55 |
| AVG Volume (30 Days) | 7.6K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 467.71 | N/A |
| EPS | ★ 124.24 | N/A |
| Revenue | ★ $5,809,000,000.00 | $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,496.48 |
| P/E Ratio | $42.05 | ★ N/A |
| Revenue Growth | ★ 7.99 | N/A |
| 52 Week Low | $2,697.00 | $30.00 |
| 52 Week High | $5,989.37 | $62.91 |
| Indicator | SEB | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 44.88 |
| Support Level | $4,725.33 | $39.93 |
| Resistance Level | $5,183.91 | $59.43 |
| Average True Range (ATR) | 224.28 | 1.68 |
| MACD | 24.16 | -0.08 |
| Stochastic Oscillator | 53.09 | 36.29 |
Seaboard Corp is a diversified group of companies that operate in agricultural, energy, and ocean transport businesses. The company is engaged in hog production, biofuel production, and pork processing in the United States; commodity trading and grain processing in Africa and South America; cargo shipping services in the U.S., Caribbean and Central and South America; sugar and alcohol production in Argentina; and electric power generation in the Dominican Republic. It also has an equity method investment in Butterball, LLC, a producer and processor of turkey products. The group's operating segments are; pork, commodity trading and milling, marine, liquid fuels, power, turkey, and others. It operates in 45 countries, with a concentration in the Caribbean, Central and South American region.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.